Initia Ltd. and Shanghai Taiyuan Life Science Announce Strategic Partnership to Expand Shockwave Therapy Market in China
Beijing, April 29, 2025 – Initia Ltd., a global leader in non-invasive shockwave therapy systems, has announced a significant strategic partnership with long-time collaborator Shanghai Taiyuan Life Science, Ltd., aimed at expanding access to its low-intensity shockwave technology across China. The agreement was commemorated at a formal signing ceremony held at the China Association of Medical Equipment (CAME) headquarters in Beijing.
This large-scale collaboration marks a major step forward in the manufacturing, clinical evaluation, regulatory registration, and commercialization of Initia’s advanced medical devices in the Chinese healthcare market. The strategic alliance strengthens Initia’s position in Asia and supports its mission to deliver innovative, non-invasive treatment solutions for a wide range of medical conditions.
Areas of Focus in the Chinese Medical Market:
- Established Treatment Fields:
- Urology devices, erectile dysfunction (ED) therapy, and orthopedic pain management
- Emerging Clinical Applications:
- Female sexual dysfunction (FSD), stress urinary incontinence (SUI), and chronic wound healing
- New Frontiers in Medical Innovation:
- Overactive bladder (OAB) and chronic kidney disease (CKD) treatment technologies
The two companies have worked closely for nearly 10 years, most notably launching the Renova shockwave therapy system in China for erectile dysfunction treatment—securing a market-leading position in this field.
“This is a unique connection between Israeli medical innovation and China’s clinical research strength,” said Niv Ein-Gal, CEO of Initia Ltd. “We’ve developed a truly harmonious collaboration with Taiyuan over the years. This next phase—scaling up manufacturing, clinical trials, and hospital partnerships—represents an exciting new chapter for both companies. For a medical technology company like ours, access to such a broad network of leading Chinese hospitals and research institutions is a dream come true.
Clinical Trials and Market Launch
Clinical trials for new applications of Initia’s shockwave technology are expected to begin in China before the end of 2025, positioning the partnership for rapid expansion and faster patient access.
This partnership reflects Initia’s commitment to medical innovation, international growth, and delivering cutting-edge therapeutic devices to meet the growing demand in China’s evolving healthcare landscape.